Recursion Pharmaceuticals (RXRX) Hits Clinical Milestones as 2025 Revenue Grows to $74.7M

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, Recursion Pharmaceuticals reported its financial results for Q4 and the full year 2025, highlighting a pivotal transition from theoretical AI drug discovery to clinical validation. The company achieved a milestone with its REC-4881 program for Familial Adenomatous Polyposis/FAP, demonstrating a 43% median reduction in total polyp burden after 12 weeks of treatment.

Beyond its wholly-owned pipeline, Recursion reached its fifth milestone with Sanofi, bringing total payments from that partnership to $134 million. To date, the company has secured over $500 million in cumulative upfront and milestone payments through its various collaborations, including significant work with Roche and Genentech on neuroscience Phenomaps.

Due to disciplined capital allocation and the successful integration of its Exscientia combination, the company has extended its projected cash runway into early 2028. Total revenue for the year rose to $74.7 million, up from $58.8 million in 2024, driven largely by milestone achievements and expanded collaboration activities. For 2026, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is focused on advancing five differentiated clinical programs and expects to report early Phase 1 data for multiple candidates, including REC-1245 and REC-7735. The company plans to engage with the FDA in H1 2026 to align on a registration pathway for its FAP program.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) operates as a clinical-stage biotechnology company that decodes biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the US.